TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06377982: A Phase I, Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Safety and Efficacy of Allogeneic Human Umbilical Cord Blood Infusion in Children with Cerebral Palsy

Sponsor: StemCyte Taiwan Co., Ltd. · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,206,400

Rescue Site Savings

+$7,389,220

Unlock Full NCT06377982 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06377982 Rescue Dossier →